- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03439605
Effect of in Vitro Haemolysis on Serum High Sensitivity Troponin T Measurements From Patients in Accident & Emergency
Investigation Into the Effect of in Vitro Haemolysis on Serum High Sensitivity Troponin T Measurement, and the Determination of an Acceptable Haemolysis Index Limit
Study Overview
Status
Conditions
Detailed Description
This study will be investigating how a common blood test for identifying heart damage (Troponin T) is affected by red blood cell damage in the blood sample (Haemolysis). It is already known that damage to the red blood cells during or after blood sample collection can cause falsely low test results however the exact amount is not clear. Some previous studies suggest that a much higher amount of red blood cell damage could be allowable when reporting the test results. This study will mimic the type of red blood cell damage that occurs in the hospital and determine what degree of damage or 'haemolysis' causes a significant reduction in the test result and therefore determine an allowable limit for safely reporting the test result. The results of this study may help provide an evidence based approach to improving current practice and may lead to less rejected blood samples, fewer repeat tests, improved treatment times in Accident and Emergency (A&E), general cost savings and an improved service to patients.
This study will be conducted as a Masters research project in Biomedical sciences (Clinical Biochemistry) as well as providing evidence to evaluate current laboratory practice. Participants attending Poole Hospital accident and emergency who are already having blood samples taken for the heart damage blood test, high sensitivity Troponin T (hs-cTnT), are chosen for this study. As the participants are already having the hs-cTnT blood test performed it means the investigators will not be determining any new information about them from the tests and they are also the population that the results of the study will benefit.
Whilst the participants are having the routine blood samples taken for their medical investigation, an extra two blood samples will be collected (a maximum of 9 ml; less than two teaspoons) following verbal permission. Only patients with the capacity to give verbal consent will be included in the study and then their blood will only be taken once. The extra blood samples will be labelled with the time and date of collection (to ensure stability when analysing). No patient identifying information will be written on the samples and they will be sent to the laboratory in a separate bag from the routine specimens to ensure anonymity.
Once received in the laboratory, one of the study samples will be analysed for hs-cTnT and haemolysis index (a measured value that equates to the amount of haemoglobin in the sample and therefore red blood cell damage). The results from these initial tests will determine if the hs-cTnT and haemolysis are within the desired range for the study.
If the sample meets the requirements for the study, a sample specific haemolysate (Haemolysed serum) will be created from the second sample. Using both samples, varying controlled degrees of haemolysis will be created and then tested for hs-cTnT. The results from the varying degrees of haemolysis will be compared to the original unhaemolysed result to determine whether a significant change in the result has occurred.
Null hypotheses:
- There is no significant difference in hs-cTnT results between baseline and up to 100 haemolysis index. There is a significant difference in hs-cTnT results between baseline and all haemolysis index levels greater than 100.
- There is no significant difference in mean percentage change of hs-cTnT up to 100 Haemolysis index and there is a significant difference in mean percentage change of hs-cTnT at all Haemolysis levels greater than 100 haemolysis index.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Dorset
-
Poole, Dorset, United Kingdom, BH15 2JB
- Poole Hospital NHSFT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients attending Poole emergency department having High Sensitivity Troponin T measurements performed on their blood as part of their medical investigations.
Exclusion Criteria:
- Serum samples with Haemolysis Index >20.
- Serum High sensitivity Troponin T result <5 ng/l and >100 ng/l
- Patients lacking capacity to give verbal consent.
- Under 18 years of age.
- Patient has previously been approached about this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The difference in measured hs-cTnT between baseline and the haemolysis groups.
Time Frame: Day one
|
Day one
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The Percentage change in hs-cTnT due to haemolysis at five groups of different troponin T levels.
Time Frame: Day one
|
Day one
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SP170327
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemolysis
-
Guy's and St Thomas' NHS Foundation TrustUniversity of OxfordNot yet recruitingHemolysis Neonatal
-
Hadassah Medical OrganizationUnknown
-
National Institutes of Health Clinical Center (CC)CompletedIsoagglutinin-Mediated Hemolysis | Probiotic ToxicityUnited States
-
Hospices Civils de LyonCompletedChronic HemolysisFrance
-
Cedars-Sinai Medical CenterWithdrawnAcute Decompensated Heart Failure | Hemolysis IntravascularUnited States
-
Aswan UniversityRecruitingObstetric Hemostasis | Intravascular Hemolysis | Major Obstetric Hemorrhage | Manual Syringing Transfusion | Pneumatic Pressure Bag TransfusionEgypt
-
Radiometer Medical ApSBispebjerg HospitalRecruiting
-
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion...Leiden University Medical CenterCompleted
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)Completed